WO2009097471A2 - Improving the appearance of nails - Google Patents
Improving the appearance of nails Download PDFInfo
- Publication number
- WO2009097471A2 WO2009097471A2 PCT/US2009/032510 US2009032510W WO2009097471A2 WO 2009097471 A2 WO2009097471 A2 WO 2009097471A2 US 2009032510 W US2009032510 W US 2009032510W WO 2009097471 A2 WO2009097471 A2 WO 2009097471A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ester
- weight
- amount
- alcohol
- thickener
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract description 69
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000004202 carbamide Substances 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000002562 thickening agent Substances 0.000 claims abstract description 19
- 208000006187 Onycholysis Diseases 0.000 claims abstract description 18
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- 150000002632 lipids Chemical class 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 206010048886 Onychoclasis Diseases 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims abstract description 5
- 230000001747 exhibiting effect Effects 0.000 claims abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 22
- 229960000878 docusate sodium Drugs 0.000 claims description 22
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 22
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 14
- 239000000787 lecithin Substances 0.000 claims description 14
- 235000010445 lecithin Nutrition 0.000 claims description 14
- 229940067606 lecithin Drugs 0.000 claims description 14
- 150000005846 sugar alcohols Polymers 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- -1 isopropyl ester Chemical class 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 2
- CFIHLFGSTIFVLP-UHFFFAOYSA-N 1-pentoxyethane-1,2-diol Chemical compound CCCCCOC(O)CO CFIHLFGSTIFVLP-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- DWKPZOZZBLWFJX-UHFFFAOYSA-L calcium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate Chemical compound [Ca+2].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC DWKPZOZZBLWFJX-UHFFFAOYSA-L 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229940018614 docusate calcium Drugs 0.000 claims description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 210000000282 nail Anatomy 0.000 description 42
- 238000009472 formulation Methods 0.000 description 23
- 239000000499 gel Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229940031663 carbomer-974p Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000004905 finger nail Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000004906 toe nail Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 150000002895 organic esters Chemical class 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IIEDMRRXMKUOQQ-UHFFFAOYSA-N 2-(cyanomethylidene)butanoic acid Chemical compound CCC(C(O)=O)=CC#N IIEDMRRXMKUOQQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 208000007209 Erythropoietic Porphyria Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028692 Nail discolouration Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 206010049274 Onychomadesis Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
- 206010036182 Porphyria acute Diseases 0.000 description 1
- 206010036186 Porphyria non-acute Diseases 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000008230 cutaneous porphyria Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000002169 ectodermal dysplasia Diseases 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- NXPHCVPFHOVZBC-UHFFFAOYSA-N hydroxylamine;sulfuric acid Chemical compound ON.OS(O)(=O)=O NXPHCVPFHOVZBC-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000024755 nail discoloration Diseases 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 208000026432 pemphigus vegetans Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- WTHDKMILWLGDKL-UHFFFAOYSA-N urea;hydrate Chemical compound O.NC(N)=O WTHDKMILWLGDKL-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 201000005976 yellow nail syndrome Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Definitions
- This disclosure relates to a composition useful in the improvement of appearance of nails. It has been discovered according the present disclosure that a topical microemulsion is able to improve the appearance of fingernails and toenails that are showing the symptoms of onycholysis, onychoschizia or onychorrhexis and/or splitting of nails.
- Onycholysis is a nail disorder frequently encountered by dermatologists. Onycholysis is characterized by a spontaneous separation of the nail plate starting at the distal free margin and progressing proximally. The nail plate is separated from the underlying and/or lateral supporting structures. Less often, separation of the nail plate begins at the proximal nail and extends to the free edge, which is seen most often in psoriasis of the nails (termed onychomadesis). Rare cases are confined to the nail's lateral borders.
- Nails with onycholysis usually are smooth, firm, and without inflammatory reaction. It is not a disease of the nail matrix, but nail discoloration may appear underneath the nail as a result of secondary infection. When onycholysis occurs, a coexistent yeast infection is suggested. Treating primary and secondary factors that exacerbate the condition is important. Left untreated, severe cases of onycholysis may result in nail bed scarring.
- Endogenous, exogenous, hereditary, and idiopathic factors can cause onycholysis.
- Amyloid and multiple myeloma Anemia (iron deficient), Bronchiectasis, Diabetes mellitus, Erythropoietic porphyria, Histiocytosis X, Hyperthyroidism, Hypothyroidism, Ischemia (peripheral, impaired circulation), Leprosy, Lupus erythematosus, Neuritis, Pellagra, Pemphigus vulgaris, Pleural effusion, Porphyria cutanea tarda, Pregnancy, Psoriatic arthritis, Reiter syndrome, Sarcoidosis, Scleroderma, Shell nail syndrome, Syphilis, and Yellow nail syndrome.
- dermatologic diseases such as: Psoriasis, Lichen planus, Dermatitis, Hyperhidrosis, Pachonychia congenital, Congenital ectodermal defect, Pemphigus vegetans, Lichen striatus, Atopic dermatitis, and Congenital abnormalities of the nail.
- Exogenous factors include microbial factors, such as Dermatophytosis (ie, Trichophyton rubrum, Trichophyton mentagrophytes infection), Yeast ⁇ Candida infection), Bacteria (Pseudomonas infection), or Virus (herpes simplex infection).
- Dermatophytosis ie, Trichophyton rubrum, Trichophyton mentagrophytes infection
- Yeast ⁇ Candida infection Yeast ⁇ Candida infection
- Bacteria Pseudomonas infection
- Virus herpes simplex infection
- Exogenous factors may also be attributed to non-microbial factors (which may be encountered at the job site, i.e., as occupational onycholysis) and subdivided into mechanical (mechanical force (trauma), repetitive minor trauma, or maceration) or chemical (allergic contact dermatitis from various nail cosmetics (methyl methacrylate monomer, formaldehyde 1-2%, nail base coat/hardeners, polymerized 2-ethylcyanoacrylate adhesive used in artificial nails, nail lacquer), gasoline, paint removers, dicyanodiamide, thioglycolate, solvents, and hydroxylamine sulphate in color developer or irritant contact dermatitis from prolonged immersion of nails in water, sugar onycholysis in confectioners/bakers, and exposure to highly destructive toxins (e.g, hydrofluoric acid).
- nail cosmetics methyl methacrylate monomer, formaldehyde 1-2%, nail base coat/hardeners, polymerized 2-ethylcyanoacrylate adhesive used in artificial
- Nail splitting known medically as onychoschizia, if the splitting is horizontal, or onychorrhexis, if the splitting is vertical, is a condition that causes splitting within the nail plate. The two conditions are also called “brittle nail syndrome.”
- Nail splitting may also be caused by nail cosmetics, nail procedures, exposures to various chemicals, such as alkalis, acids, thioglycolates, solvents, salt and sugar solutions. Damage to the nail may also be a factor in the development of nail splitting. Skin diseases, such as psoriasis and Sjogren's syndrome, endocrine diseases, malnutrition, and oral medications made from vitamin A may also be causative factors in nail splitting.
- Nails which have shown splitting have also been treated with similar formulations to those shown to treat onycholysis. In each case the nails splits have improved upon daily application of the formulation, after hand washing, for as few as five days.
- the present disclosure also relates to a method of improving the appearance of fingernails or toenails displaying onycholysis, onychoschizia or onychorrhexis comprising topically applying to the nail of the human or animal certain compositions.
- the composition comprises one or more biocompatible organic solvents, a polar lipid, at least one surfactant, water, urea and a thickener.
- the organic solvents comprise an ester and/or a dihydric and/or polyhydric alcohol.
- the composition comprises about 2 to about 30% by weight of the ester and about 2 to about 20% by weight of the dihydric and/or polyhydric alcohol.
- topical administration is meant directly laying or spreading upon epidermal tissue, especially finger nails and toenails, including the skin areas around those nails.
- comprising is meant that various other compatible components such as inert ingredients, occlusive agents, and cosmetic vehicles, cosmetics and/or medicaments can be conjointly employed in the compositions and methods of this invention.
- the term “comprising” thus encompasses and includes the more restrictive terms “consisting of and “consisting essentially of which characterize the use of the essential ingredients in the manner disclosed herein.
- afflicted sites is meant a localized area of the unsightly nails, and the immediately surrounding area.
- application sites is meant a site suitable for application via a mechanical release device or dressing, e.g., at the distal end of the nails, on the top of the nails, at the proximal area of the nails, etc.
- compositions of the present invention contain less than about 10%, preferably less than 3.5%, more preferably less than about 1%, and most preferably less than about 0.5%, of any specific compound, or member of the group of compounds, described by this term. As used herein, all percentages and ratios are by weight of the total composition unless otherwise specified.
- compositions employed in this disclosure comprise a polar lipid, such as lecithin or phosphotidylcholine, and two biocompatible organic solvents, one chosen from the group of esters and one chosen from the group of liquid dihydric and polyhydric alcohols, a surfactant, water, and urea, at a pH of about 5 to about 8.5 and preferably of about 6 to about 7.5.
- the compositions of this disclosure may additionally contain other optional components that reduce skin irritation, or enhance their cosmetic appeal or acceptability, e.g, emollients, pigments, fragrances, perfumes, preservatives and the like.
- the compositions of this disclosure may or may not contain a cosmetic agent and/or pharmaceutically-active agent capable of producing or possessing local activity, with the composition of this disclosure as the carrier.
- Typical polar lipids employed are lecithin and phosphotidylcholine.
- the lecithin or phosphatidylcholine is of a high quality, pharmaceutical grade.
- Appropriate lecithin and phosphatidylcholine maybe obtained as commercially available soya lecithin or soya phosphatidylcholine.
- soya lecithin is used in the composition of this disclosure.
- the biocompatible organic ester solvents may be any non-toxic ester in which the polar lipid and urea are soluble.
- the esters are fatty mono esters having a structure, obtainable by replacing the active hydrogen of a fatty acid having 4 to 22 carbon atoms and more typically having 8 to 18 carbon atoms by the alkyl group of a monohydric alcohol, a particular example being 12 carbon atoms.
- the fatty acid can be saturated or unsaturated and more typically is saturated.
- the monohydric alcohol typically contains 2 to 8 carbon atoms and more typically 2 to 5 carbon atoms, a particular example being 3 carbon atoms.
- Acceptable esters for this purpose include, but are not limited to isopropyl esters.
- the ester is isopropyl myristate or isopropyl palmitate, with isopropyl myristate being particularly preferred.
- the biocompatible organic dihydric and polyhydric alcohol solvents may be any nontoxic dihydric alcohol or polyhydric alcohol in which the polar lipid and urea are soluble.
- Acceptable dihydric and polyhydric alcohols for this purpose include, but are not limited to di- and tri-alcohol alkanes.
- the alcohols typically contain 3 to 8 carbon atoms and more typically 3 to 5 carbon atoms and are saturated alcohols.
- the polyalcohol is propylene glycol or glycerol, with propylene glycol being particularly preferred.
- compositions of the present disclosure typically contain about 2 to 30% by weight and more typically 4 to 10 % by weight of the ester and about 2 to about 20 % by weight and more typically 2 to about 10 % weight of the dihydric/polyhydric alcohol.
- the polar lipid is typically dissolved in the organic ester solvent and dihydric or polyhydric alcohol solvent at mass ratios from about 5:1 :1 to about 1 :5:5.
- the polar lipid and organic ester solvent and polyalcohol solvent are mixed in equal mass ratios.
- soya lecithin, isopropyl myristate, and propylene glycol are mixed in equal mass ratios and mixed until the lecithin is evenly distributed. This is referred to as the solvent-polar lipid mixture.
- a surfactant is included in the formulation typically at a concentration of about 0.5% to about 20% of the final composition mass.
- a polycationic active agent it has been found, according to this disclosure that non-ionic or cationic surfactants are preferred.
- anionic, cationic or non-ionic surfactants are quite acceptable.
- the surfactant is one which is compatible with administration in vivo without elicitation of undesirable side effects.
- One preferred surfactant is docusate sodium and its more water soluble form, docusate sodium benzoate.
- ionic or non-ionic surfactants such as polysorbate 80, Tween 80, poloxamer, ibuprofen, docusate calcium, tetradecylrrimethylammonium bromide, pentaoxyethylene glycol monododecyl ether, or triethanolamine laureth sulfate.
- a cosmetic or pharmaceutically active compound if desired, may be added and dissolved.
- active compounds include anti-proliferative/anti- inflammatory compound that can ameliorate other contributors to the unsightly appearance of fingernails and toenails or decrease the response time of the compositions.
- compositions of this disclosure do not require and are preferably free of such active agents.
- an amount of urea preferably as a thickened aqueous solution, can be added to the surfactant-solvent- polar lipid mixture.
- the urea is typically added so that the urea concentration about 1% to about 20%, more typically about 1% to about 15%and even more typically about 5% and 10% by mass of the final composition mass.
- the thickener is selected from common National Formulary thickening agents including, but not limited to appropriate polymer weights of polyethylene glycol, polyvinylpyrrolidone, carbomer, alginates, gums and methylcellulose.
- the amount of thickener is typically about 0.01 to about 5% by weight and more typically about 0.05% to about 5%.
- about 5 grams of a 10% aqueous solution of urea, containing 0.9% Carbomer 974P is added to about 100 grams of the surfactant-solvent-polar lipid mixture.
- this is a choice readily made by those skilled in the art, once aware of the present disclosure, depending on the particular formulation being prepared.
- the pH is adjusted to a typical pH of about 5 to about 8.5 and more typically to a 6 to 7.5. This can be accomplished, for example, by addition of aqueous sodium hydroxide, as the compositions initially tend to have an acid pH.
- the pharmaceutically active agent tends to produce very alkaline solutions
- addition of acid to reduce the pH would be desirable. This can be accomplished by addition of citric acid or a biological buffer such as sodium carbonate or potassium phosphate.
- citric acid or a biological buffer such as sodium carbonate or potassium phosphate.
- compositions can contain auxiliary agents including those conventionally known and/or used in this art such as, but not limited to, preservatives and fragrances.
- MQX-GEL a first gel composition
- a MQX-GEL may be prepared by mixing lecithin organogel (L.O.), as a 1 :1:1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O. and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
- L.O. lecithin organogel
- LID oil a 1:1 [m/m] mixture of L.O. and docusate sodium
- the solubilized active ingredients may then be added to MQX-GEL.
- Excipients which may be useful in solubilizing an active ingredient include L.O., propylene glycol, isopropyl myristate, limonene, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
- formulations described above have been prepared, use of the formulations is a simple matter of applying the formulation to affected areas where cutaneous delivery is desired.
- formulations as described above are rubbed over the affected nail area of the fingers or the toes.
- the normal appearance of non-split nails has been restored within five days with daily application. Treatment is repeated as symptoms reappear.
- formulations as described above are rubbed over the affected nail area of the fingers or the toes.
- the normal appearance of nails has been restored within four months with daily application. Treatment is repeated as symptoms reappear.
- compositions of this invention are applied topically as frequently as required as long as local reactions do not become a problem.
- Lecithin organogel** 100 gm Docusate sodium powder 50 gm
- Distilled water 245 ml *LID oil is a 1 : 1 mixture of lecithin organogel:docusate sodium on a mass basis.
- **L.O. is a 1:1 :1 mixture of lecithin, isopropyl myristate and propylene glycol.1.
- the LID was added to L.O. and heated.
- MQX-GEL may just as easily be prepared as follows:
- the L.O. was heated and the docusate sodium benzoate powder was stirred into the heated L.O. until a smooth solution is prepared.
- the water was heated and the thickener and urea were dissolved into the water, and the thickened urea solution was then thoroughly mixed with the docusate sodium containing solution of L.O.
- the result was a consistent, transparent, amber colored gel with a pH of about 6.0.
- a further method of making MQX-GEL is as follows:
- the LID and L.O. were mixed well and a heated solution of water, the thickener and the urea was prepared and added to the LID-L.O. solution.
- the result was a consistent, transparent, amber colored gel with a pH of about 6.0.
- MQX-GEL can also be prepared with other ratios of the three constituents of the lecithin organogel.
- the ratio of lecithin organogel (L.O. #2), is a 1:0.9:0.1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O.#2 and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
- the final concentrations are:
- a solubilized active ingredients if desired, can then be added to MQX-GEL.
- Excipients which may be useful in solubilizing an active ingredient include L.O.#2, propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
- Carbomer 974P and Methylcellulose are added to thicken the urea- water of step 3. 5.
- the solution from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
- the pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick microemulsion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010545177A JP2011520773A (en) | 2008-01-30 | 2009-01-30 | Improved nail appearance |
CA2713496A CA2713496A1 (en) | 2008-01-30 | 2009-01-30 | Improving the appearance of nails |
EP09705600A EP2234582A2 (en) | 2008-01-30 | 2009-01-30 | Improving the appearance of nails |
AU2009209124A AU2009209124A1 (en) | 2008-01-30 | 2009-01-30 | Improving the appearance of nails |
CN2009801034553A CN102099002A (en) | 2008-01-30 | 2009-01-30 | Improving the appearance of nails |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/022,833 | 2008-01-30 | ||
US12/022,833 US20090191138A1 (en) | 2008-01-30 | 2008-01-30 | Novel topical formulations for improving the appearance of nails |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009097471A2 true WO2009097471A2 (en) | 2009-08-06 |
WO2009097471A3 WO2009097471A3 (en) | 2016-03-24 |
Family
ID=40899454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/032510 WO2009097471A2 (en) | 2008-01-30 | 2009-01-30 | Improving the appearance of nails |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090191138A1 (en) |
EP (1) | EP2234582A2 (en) |
JP (1) | JP2011520773A (en) |
KR (1) | KR20100131972A (en) |
CN (1) | CN102099002A (en) |
AU (1) | AU2009209124A1 (en) |
CA (1) | CA2713496A1 (en) |
WO (1) | WO2009097471A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013522590A (en) * | 2010-03-12 | 2013-06-13 | 独立行政法人理化学研究所 | Clarification reagent for biological materials and use thereof |
EP3603650A1 (en) | 2018-08-01 | 2020-02-05 | Edix O Sarl | Injectable and prolonged action compositions for use in the treatment of diseases of the nail and/or to accelerate nail growth |
WO2020025683A1 (en) | 2018-08-01 | 2020-02-06 | Edix-O Sarl | Injectable prolonged-action compositions for use in the treatment of nail disease and/or for promoting nail growth |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
CN103492852B (en) * | 2011-04-28 | 2016-08-17 | 独立行政法人理化学研究所 | The transparence method of biomaterial and utilization thereof |
EP2711682B1 (en) | 2011-05-20 | 2019-07-10 | Riken | Clarifying reagent for biological materials and use thereof |
US8835369B2 (en) | 2012-06-04 | 2014-09-16 | L'oreal | Odorless acetone-free nail polish removing composition |
JP6433901B2 (en) | 2013-08-14 | 2018-12-05 | 国立研究開発法人理化学研究所 | Composition for preparing biological material with excellent light transmittance and use thereof |
US10058159B2 (en) * | 2016-12-01 | 2018-08-28 | Richard L. Kronenthal | Sterile compositions for human cosmetic products |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985661A (en) * | 1956-02-06 | 1961-05-23 | American Cyanamid Co | Preparation of 2(omicron-aminophenyl)-benzimidazole |
BE599143A (en) * | 1960-01-18 | |||
NL134354C (en) * | 1963-05-23 | |||
US3646049A (en) * | 1970-03-05 | 1972-02-29 | Merck & Co Inc | Acylaminobenzimidazole derivatives |
US5861142A (en) * | 1996-03-25 | 1999-01-19 | Schick; Mary Pichler | Method for promoting hair, nail, and skin keratinization |
IL138889A0 (en) * | 1998-04-17 | 2001-11-25 | Bertek Pharm Inc | Topical formulations for the treatment of nail fungal diseases |
US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
DE10126501A1 (en) * | 2001-05-30 | 2002-12-12 | Aventis Pharma Gmbh | Composition used for detaching abnormal keratin material e.g. warts or fungally damage nails, comprises mixture of urea, film former and water or aqueous alcohol |
US6908941B2 (en) * | 2002-06-06 | 2005-06-21 | Nicholas V. Perricone | Hair and nail treatments using alkanolamines |
US20070014743A1 (en) * | 2002-09-27 | 2007-01-18 | Birnbaum Jay E | Subunguicide, and method for treating onychomycosis |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
-
2008
- 2008-01-30 US US12/022,833 patent/US20090191138A1/en not_active Abandoned
-
2009
- 2009-01-30 EP EP09705600A patent/EP2234582A2/en not_active Withdrawn
- 2009-01-30 CN CN2009801034553A patent/CN102099002A/en active Pending
- 2009-01-30 CA CA2713496A patent/CA2713496A1/en not_active Abandoned
- 2009-01-30 AU AU2009209124A patent/AU2009209124A1/en not_active Abandoned
- 2009-01-30 JP JP2010545177A patent/JP2011520773A/en active Pending
- 2009-01-30 WO PCT/US2009/032510 patent/WO2009097471A2/en active Application Filing
- 2009-01-30 KR KR1020107017171A patent/KR20100131972A/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013522590A (en) * | 2010-03-12 | 2013-06-13 | 独立行政法人理化学研究所 | Clarification reagent for biological materials and use thereof |
EP3603650A1 (en) | 2018-08-01 | 2020-02-05 | Edix O Sarl | Injectable and prolonged action compositions for use in the treatment of diseases of the nail and/or to accelerate nail growth |
WO2020025683A1 (en) | 2018-08-01 | 2020-02-06 | Edix-O Sarl | Injectable prolonged-action compositions for use in the treatment of nail disease and/or for promoting nail growth |
Also Published As
Publication number | Publication date |
---|---|
US20090191138A1 (en) | 2009-07-30 |
KR20100131972A (en) | 2010-12-16 |
EP2234582A2 (en) | 2010-10-06 |
JP2011520773A (en) | 2011-07-21 |
AU2009209124A1 (en) | 2009-08-06 |
CA2713496A1 (en) | 2009-08-06 |
WO2009097471A3 (en) | 2016-03-24 |
CN102099002A (en) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090191138A1 (en) | Novel topical formulations for improving the appearance of nails | |
US10821075B1 (en) | Compositions for topical application of a medicaments onto a mammalian body surface | |
CA2567575C (en) | Organo-gel formulations for therapeutic applications | |
KR101420599B1 (en) | Compositions containing anti-acne agents and the use thereof | |
US20170087073A1 (en) | Mild leave-on skin care compositions | |
DK1853303T3 (en) | STABILIZED COMPOSITIONS FOR TOPIC ADMINISTRATION AND PROCEDURES FOR PREPARING IT | |
IL180691A (en) | Organo-gel formulations for therapeutic applications | |
JP2001522804A (en) | Penetration enhancement and stimulation reduction system | |
JPH11507350A (en) | Topical vehicle containing solubilized and stabilized azelaic acid | |
JP7421558B2 (en) | Semi-solid oily pharmaceutical composition containing pirfenidone applied to tissue repair | |
JP2005524651A (en) | Topical dapsone for the treatment of acne | |
CA2365660A1 (en) | Treatment for skin | |
JP2002161027A (en) | Method for suppressing inflammation and erythema and composition therefor | |
JP2022501345A (en) | Repair of lipid barriers | |
CN107233222A (en) | A kind of composition with liquid crystal structure and its application in cosmetics | |
JPH05331066A (en) | Composition for treatment of acne vulgaris | |
JPH03157311A (en) | Cosmetic for common acne | |
JPS63183518A (en) | Composition for hair | |
JPH02311411A (en) | Hair-culturing agent | |
JPH0354081B2 (en) | ||
JP2017214343A (en) | Therapeutic agent for acne-vulgaris | |
KR0153203B1 (en) | Cosmetic composition for moisturising and softening | |
RU2112505C1 (en) | Sulfur ointment | |
CN114767563A (en) | Mild and mild quick-acting depilatory composition and application thereof | |
WO2011001165A2 (en) | Formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980103455.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09705600 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009209124 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 586956 Country of ref document: NZ Ref document number: 2009705600 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2713496 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010545177 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20107017171 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009209124 Country of ref document: AU Date of ref document: 20090130 Kind code of ref document: A |